Biggest News Aggregation in the World
📰 From Maxcyte News

From Maxcyte News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from From Maxcyte. Real-time updates on events, politics, business and more.

MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.
United States Doug Doerfler Maria Osipova Asia Pacific Rna Health Conference Maxcyte Inc

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, ...
Maria Osipova Doug Doerfler Vittoria Biotherapeutics Nicholas Siciliano Maxcyte Inc Maxcyte Inc Aug

MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.
Maria Osipova Doug Doerfler Maxcyte Inc Aug Medicine Inc Maxcyte Inc From Maxcyte

MaxCyte signs strategic platform license with Lyell Immunopharma

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company.
Doug Doerfler Lyell Immunopharma Maria Osipova Lyell Immunopharma Inc Maxcyte Inc Maxcyte Inc Aug

MaxCyte signs strategic platform license with LG Chem to advance its allogeneic CAR-T programs

MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science...
South Korea South Korean Laura Thomson Doug Doerfler Maxcyte Inc Lg Chem Ltd

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science